Les AINS sont-ils susceptibles de compromettre l’efficacité cardiopréventive de l’aspirine?

Karila-Cohen, 2000, Aspirine et prévention du risque cardiovasculaire, Rev Med Interne, 21, 35, 10.1016/S0248-8663(00)88723-8 Silverstein, 2000, Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial, JAMA, 284, 1247, 10.1001/jama.284.10.1247 Lisse, 2003, Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis. A randomized, controlled trial, Ann Intern Med, 139, 539, 10.7326/0003-4819-139-7-200310070-00005 Farkouh, 2004, Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial, Lancet, 364, 675, 10.1016/S0140-6736(04)16894-3 Bresalier, 2005, Cardiovacular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med, 352, 1092, 10.1056/NEJMoa050493 Solomon, 2005, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N Engl J Med, 52, 1071, 10.1056/NEJMoa050405 Berenbaum, 2003, NSAIDs and aspirin: friends or foes?, J Bone Spine, 70, 89, 10.1016/S1297-319X(02)00023-4 Baigent, 2003, Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. A reappraisal, Arthritis Rheum, 48, 12, 10.1002/art.10738 Flipo, 2004, Conséquences de l’association anti-inflammatoires non stéroïdiens et aspirine à visée cardiovasculaire chez le sujet âgé, Rev Rhum, 71, S173, 10.1016/S1169-8330(04)80023-1 Bonnet, 2005, Review article: a cardiologist's view of the risks and benefits of cyclo-oxygenase-2 inhibitors, aspirin and other non-steroidal anti-inflammatory drugs, Aliment Pharmacol Ther Symp Ser, 1, 11, 10.1111/j.1746-6342.2005.00014.x Catella-Lawson, 2001, Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, N Engl J Med, 345, 1809, 10.1056/NEJMoa003199 Ouellet, 2001, A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin, PNAS, 98, 14583, 10.1073/pnas.251543298 Greenberg, 2000, A new cyclooxygenase-2 inhibitor, rofecoxib (Vioxx), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers, J Clin Pharmacol, 40, 1509, 10.1177/009127000004001224 Wilner, 2002, Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers, J Clin Pharmacol, 42, 1027, 10.1177/009127002401102858 Van Ryn, 2004, Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers, J Clin Pharmacol, 44, 777, 10.1177/0091270004266623 Capone, 2005, Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects, J Am Coll Cardiol, 45, 1295, 10.1016/j.jacc.2005.01.045 MacDonald, 2003, Effect of ibuprofen on cardioprotective effect of aspirin, Lancet, 361, 573, 10.1016/S0140-6736(03)12509-3 Kurth, 2003, Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs, Circulation, 108, 1191, 10.1161/01.CIR.0000087593.07533.9B Kimmel, 2004, The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin, J Am Coll Cardiol, 43, 985, 10.1016/j.jacc.2003.08.064 Ko, 2002, Nonsteroidal antiinflammatory drugs after acute myocardial infarction, Am Heart J, 143, 475, 10.1067/mhj.2002.121270 Patel, 2004, Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction, Arch Intern Med, 164, 852, 10.1001/archinte.164.8.852 Cheema, 2004, Should people on aspirin avoid ibuprofen? A review of the literature, Cardiology in Review, 12, 174, 10.1097/01.crd.0000107892.83612.9d Greenberg, 2005, Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists, Arthritis Care Res, 53, 12, 10.1002/art.20905